Article
Nivolumab Approved for Expanded Indication
Nivolumab is now approved to treat metastatic squamous non-small cell lung cancer, although adverse effects such as serious immune-mediated...
“Mortality trends are the gold standard for evidence of progress against cancer,” so it’s good news that cancer-related death rates are continuing to decline, according to the National Cancer Institute’s (NCI’s) Annual Report to the Nation on the Status of Cancer, 1975-2011. Between 2002 and 2011, age-adjusted rates for all cancers combined declined 0.5% for both men and women. Among men, rates have dropped by about 1.8% per year; among women, 1.4%; and among children, roughly 2%.
Related: How Much Is Too Much Cancer Screening?
Death rates during this same 10-year period among men declined for 10 of the 17 most common cancers and among women for 13 of the top cancers. The largest declines in incidence for men were in cancers of the colon and rectum, lung and bronchus, and prostate. Women saw the biggest declines in cancers of the colon, rectum, and cervical spine.
Related: Nivolumab Approved for Expanded Indication
The rate of new cases of lung cancer also continued a downward trend, in sync with the smoking rate. But oral/oropharyngeal cancers have increased among white men, perhaps associated with higher incidence of human papilloma virus, the researchers suggest.
Despite the dropping mortality rates, all is not bright. Thyroid and kidney cancer incidence rates are on the rise in both men and women, although no increase in mortality has been noted. Liver cancer cases and death rates are also increasing; this may reflect, in part, higher rates of hepatitis C and/or behavioral risk factors, such as alcohol abuse, the NCI report says.
Related: Timely Assessment of Cancer Symptoms
The incidence and mortality rates are increasing as well for uterine cancer among whites, blacks, and Asian Pacific Islander women, with the largest increase seen in black women. The cause of the increases is unknown, the report says.
Nivolumab is now approved to treat metastatic squamous non-small cell lung cancer, although adverse effects such as serious immune-mediated...
Researchers surveyed 1,000 adults to assess acceptance rates of overdetection of cancerous lesions that would otherwise not have caused any...
CLL incidence by race and location